RT Journal Article
SR Electronic
T1 Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects on brain
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.13.21267480
DO 10.1101/2021.12.13.21267480
A1 Rachel L. Kember
A1 Rachel Vickers-Smith
A1 Heng Xu
A1 Sylvanus Toikumo
A1 Maria Niarchou
A1 Hang Zhou
A1 Emily Hartwell
A1 Richard C. Crist
A1 Christopher T. Rentsch
A1 VA Million Veteran Program
A1 Lea K. Davis
A1 Amy C. Justice
A1 Sandra Sanchez-Roige
A1 Kyle M. Kampman
A1 Joel Gelernter
A1 Henry R. Kranzler
YR 2021
UL http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267480.abstract
AB Despite an estimated twin heritability of ∼50%, genome-wide association studies (GWAS) of opioid use disorder (OUD) have revealed few genome-wide significant (GWS) loci, with replicated findings only in European-ancestry individuals. To identify novel loci, including those in non-European ancestries, and improve our understanding of the biology of OUD, we conducted a cross-ancestry meta-analysis using the Million Veteran Program (MVP). OUD cases in MVP had at least 1 International Classification of Diseases (ICD)-9 or ICD-10 code for opioid abuse or dependence (N=31,473). Opioid-exposed controls (N=394,471) had one or more outpatient opioid prescription fills. We conducted GWAS for each major ancestral group in MVP: African Americans (AAs; N=88,498), European Americans (EAs; N=302,585), and Hispanic Americans (HAs; N=34,861), followed by a cross-ancestry meta-analysis. Ten loci were GWS in the cross-ancestry meta-analysis, 8 of them novel. In addition to the known coding variant rs1799971 in OPRM1, which was the lead SNP genome-wide (p=6.78×10−10), and a recently reported exonic variant in FURIN, we identified intronic variants in RABEPK, FBXW4, NCAM1, and KCNN1. Ancestry-specific analyses identified an additional novel locus for each of the 3 ancestry groups. A supplementary meta-analysis within EAs that included MVP and other samples identified a locus in TSNARE1, which was also GWS in the cross-ancestry meta-analysis of all datasets. Gene-based association analyses identified 1 gene in AAs (CHRM2) and 3 in EAs (OPRM1, DRD2, and FTO). Significant genetic correlations (rg’s) were identified for 127 traits, including positive correlations with schizophrenia, problematic alcohol use, and major depressive disorder. The most significantly enriched cell type group was the central nervous system with gene-expression enrichment identified in brain regions previously associated with substance use disorders. With a case sample 50% larger than that of the previous largest GWAS, we identified 14 loci for OUD, including 12 novel loci, some of which were ancestry-specific. These findings increase our understanding of the biological pathways involved in OUD, which can inform preventive, diagnostic, and therapeutic efforts and thereby help to address the opioid epidemic.Competing Interest StatementDr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals and Sophrosyne Pharmaceuticals, a consultant to Sobrera Pharmaceuticals and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists" filed January 24, 2018. The other authors have no disclosures to make.Funding StatementThis work was supported by Merit Review Awards from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Service (# I01 BX003341) and Clinical Science Research and Development Service (# I01 CX001734; the VISN 4 Mental Illness Research, Education, and Clinical Center; NIAAA grant K01 AA028292 (to RLK); and NIDA grant DA046345. The views expressed in this article are those of the authors and do not necessarily represent the position or policy of the Department of Veterans Affairs or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board (IRB) of Central Veterans Affairs gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full summary-level association data will be made available through dbGaP upon publication